ResMed 8-K (2.02, 8.01, 9.01): reported results of operations

ResMed reported first-quarter fiscal 2027 revenue of $1.415 billion, up 6%, and diluted EPS of $2.92, up 23%; it returned more than $1 billion to shareholders and completed the MatrixCare divestiture.